dalteparin has been researched along with Melanoma in 8 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental metastasis of MV3 cells in mice confirmed the relevance of VLA-4 for metastatic dissemination." | 1.38 | The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. ( Bendas, G; Casu, B; Naggi, A; Schlesinger, M; Schmitz, P; Torri, G; Zeisig, R, 2012) |
| " Pharmacokinetic studies determined optimal dosing for clinically relevant anticoagulant levels in mice." | 1.33 | Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. ( Choi, SH; Stevenson, JL; Varki, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ataabadi, FV | 1 |
| Oveissi, F | 1 |
| Etebari, M | 1 |
| Taheri, A | 1 |
| Kerk, N | 1 |
| Strozyk, EA | 1 |
| Pöppelmann, B | 1 |
| Schneider, SW | 2 |
| Schlesinger, M | 2 |
| Schmitz, P | 3 |
| Zeisig, R | 1 |
| Naggi, A | 2 |
| Torri, G | 2 |
| Casu, B | 1 |
| Bendas, G | 3 |
| Wojtukiewicz, MZ | 1 |
| Kozlowski, L | 1 |
| Ostrowska, K | 1 |
| Dmitruk, A | 1 |
| Zacharski, LR | 1 |
| Gerber, U | 1 |
| Schütze, N | 1 |
| Jüngel, E | 1 |
| Blaheta, R | 1 |
| Bauer, AT | 1 |
| Suckau, J | 1 |
| Frank, K | 1 |
| Desch, A | 1 |
| Goertz, L | 1 |
| Wagner, AH | 1 |
| Hecker, M | 1 |
| Goerge, T | 1 |
| Umansky, L | 1 |
| Beckhove, P | 1 |
| Utikal, J | 1 |
| Gorzelanny, C | 1 |
| Diaz-Valdes, N | 1 |
| Umansky, V | 1 |
| Simonis, D | 1 |
| Fritzsche, J | 1 |
| Stevenson, JL | 1 |
| Choi, SH | 1 |
| Varki, A | 1 |
1 trial available for dalteparin and Melanoma
| Article | Year |
|---|---|
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; C | 2003 |
7 other studies available for dalteparin and Melanoma
| Article | Year |
|---|---|
Preparation of chitosan nanoparticles for simultaneous drug delivery of dacarbazine and enoxaparin in melanoma.
Topics: Chitosan; Dacarbazine; Drug Delivery Systems; Enoxaparin; Humans; Melanoma; Nanoparticles | 2023 |
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
Topics: Anticoagulants; Cell Line, Tumor; Endothelial Cells; Enoxaparin; Flow Cytometry; Heparin; Heparin, L | 2010 |
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Topics: Acetylation; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Cell Adhesion; Cell Line, T | 2012 |
Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Topics: Anticoagulants; Carcinogenesis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cysteine-Rich Protei | 2013 |
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.
Topics: ADAM Proteins; ADAMTS13 Protein; Animals; Blood Coagulation; Blood Platelets; Disease Models, Animal | 2015 |
Binding between heparin and the integrin VLA-4.
Topics: Acoustics; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biosensing Techniques; Cell Ad | 2009 |
Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Topics: Animals; Anticoagulants; Cell Line, Tumor; Disaccharides; Factor Xa; Fibrinolytic Agents; Fondaparin | 2005 |